Semaglutide 7.2 mg: A Breakthrough in Obesity Management
Recent developments by Novo Nordisk signify significant progress in obesity treatment with the results from the STEP UP trial. This phase 3b clinical trial aimed to assess the efficacy of subcutaneous semaglutide 7.2 mg, alongside semaglutide 2.4 mg and placebo, over a duration of 72 weeks. The trial involved 1,407 adults struggling with obesity, all of whom were supported by lifestyle interventions.
Impressive Weight Loss Results
The STEP UP trial successfully demonstrated that those using semaglutide 7.2 mg experienced a superior weight loss of 20.7% after 72 weeks, significantly higher compared to 17.5% with semaglutide 2.4 mg and just 2.4% with placebo. This landmark outcome illustrates semaglutide 7.2 mg's potential to aid individuals in achieving meaningful weight loss.
Adherence and Weight Loss Outcomes
When results were analyzed based on treatment adherence, 33.2% of participants treated with semaglutide 7.2 mg achieved a remarkable weight loss of 25% or more. In contrast, only 16.7% of those on semaglutide 2.4 mg and none on placebo reached this milestone. Even under the treatment policy estimand, which considers all participants regardless of adherence, the semaglutide 7.2 mg group achieved a weight loss of 18.7%.
Safety Profile and Patient Experience
In terms of safety, semaglutide 7.2 mg presented a favorable profile, with most reported adverse events being mild to moderate gastrointestinal issues that decreased over time. Such a profile aligns with the expectations for GLP-1 receptor agonists, making it a viable option for long-term weight management.
Expert Perspectives on Trial Results
Martin Holst Lange, Executive Vice President for Development at Novo Nordisk, expressed enthusiasm regarding the trial results, noting, "We are very pleased to demonstrate 20.7% weight loss ... with a safety and tolerability profile comparable to semaglutide 2.4 mg." He emphasized that the findings reinforce semaglutide's clinical role as a potent treatment for obesity, joining the existing evidence from Wegovy®, which is recognized not only for weight management but also for cardiovascular risk reduction.
Next Steps and Future Trials
Looking ahead, Novo Nordisk is preparing to unveil results from the STEP UP T2D trial, which evaluates the efficacy of semaglutide 7.2 mg in adults with both type 2 diabetes and obesity. These anticipated results are expected to deepen the understanding of semaglutide's capabilities and broaden its application in diabetes management.
About Novo Nordisk
Novo Nordisk is a global leader in healthcare, specializing in chronic diseases, and is rooted in a legacy of pioneering treatments for diabetes since its inception in 1923. With a workforce of around 72,000 distributed across 80 countries, Novo Nordisk is committed to enhancing access to innovative medicines and striving towards a future where serious diseases can be effectively managed or eradicated.
Contact Information for Media and Investors
For further inquiries about this study or the company, interested parties can reach out to:
Media Contacts:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investor Contacts:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Frequently Asked Questions
What is the STEP UP trial about?
The STEP UP trial is a phase 3b study investigating the efficacy of semaglutide 7.2 mg for weight loss in adults with obesity.
What kind of weight loss does semaglutide 7.2 mg achieve?
Participants in the trial achieved an average weight loss of 20.7% after 72 weeks with semaglutide 7.2 mg.
What were the safety concerns for semaglutide 7.2 mg?
The most common adverse events were mild gastrointestinal issues, which decreased over time during the trial.
When will the results from STEP UP T2D be available?
The results from STEP UP T2D, which explores semaglutide 7.2 mg in adults with type 2 diabetes and obesity, are expected soon.
What is Novo Nordisk's mission?
Novo Nordisk aims to change the lives of people with chronic diseases by advancing treatment innovations and increasing access to their medications.
